Javascript must be enabled to continue!
Bupropion With Clozapine: Case Reports of Seizure After Coadministration
View through CrossRef
Background:
Clozapine is more effective than other atypical antipsychotics for treatment resistant schizophrenia, but has serious side effects. Clozapine has an estimated cumulative seizure risk of 10% in patients treated for 3.8 years. Bupropion can also induce seizures and its estimated risk is 0.4% at recommended doses. While some risk factors for seizures are known, much remains unknown about predicting seizure risk. Cases: We present 2 cases of seizures in patients treated with clozapine and bupropion without a seizure history. In the first case, a patient with schizoaffective disorder treated with dual antipsychotic therapy had a witnessed generalized tonic–clonic seizure. With the exception of bupropion/naltrexone which was started 2.5 months prior for weight loss, she had not had any recent medication changes. In the second case, a patient with schizoaffective disorder was treated with clozapine and was prescribed bupropion SR for smoking cessation for an extended duration. He had cut back on cigarette use in the 2 months prior to reporting “spells.” The neurologist’s assessment was probable epileptic seizures which resolved after the bupropion was stopped and divalproex was started for seizure prophylaxis.
Conclusion:
Clozapine and bupropion are known to lower the seizure threshold, but little information is available regarding the risk when used in combination. It is unclear whether these agents, when used in combination, have additive seizure risk or possible synergistic effects. Bupropion should be used cautiously in patients treated with clozapine. Safer agents that do not lower the seizure threshold should be utilized whenever possible.
Title: Bupropion With Clozapine: Case Reports of Seizure After Coadministration
Description:
Background:
Clozapine is more effective than other atypical antipsychotics for treatment resistant schizophrenia, but has serious side effects.
Clozapine has an estimated cumulative seizure risk of 10% in patients treated for 3.
8 years.
Bupropion can also induce seizures and its estimated risk is 0.
4% at recommended doses.
While some risk factors for seizures are known, much remains unknown about predicting seizure risk.
Cases: We present 2 cases of seizures in patients treated with clozapine and bupropion without a seizure history.
In the first case, a patient with schizoaffective disorder treated with dual antipsychotic therapy had a witnessed generalized tonic–clonic seizure.
With the exception of bupropion/naltrexone which was started 2.
5 months prior for weight loss, she had not had any recent medication changes.
In the second case, a patient with schizoaffective disorder was treated with clozapine and was prescribed bupropion SR for smoking cessation for an extended duration.
He had cut back on cigarette use in the 2 months prior to reporting “spells.
” The neurologist’s assessment was probable epileptic seizures which resolved after the bupropion was stopped and divalproex was started for seizure prophylaxis.
Conclusion:
Clozapine and bupropion are known to lower the seizure threshold, but little information is available regarding the risk when used in combination.
It is unclear whether these agents, when used in combination, have additive seizure risk or possible synergistic effects.
Bupropion should be used cautiously in patients treated with clozapine.
Safer agents that do not lower the seizure threshold should be utilized whenever possible.
Related Results
Hydatid Disease of The Brain Parenchyma: A Systematic Review
Hydatid Disease of The Brain Parenchyma: A Systematic Review
Abstarct
Introduction
Isolated brain hydatid disease (BHD) is an extremely rare form of echinococcosis. A prompt and timely diagnosis is a crucial step in disease management. This ...
Supporting successful clozapine treatment
Supporting successful clozapine treatment
The overall objective of this thesis is to support successful clozapine treatment, by firstly expanding the knowledge on the predictability of early clozapine discontinuation, seco...
Community Clozapine Initiation Practice
Community Clozapine Initiation Practice
AimsTo establish the proportion of CMHT Preston service users with schizophrenia who met the NICE standard (CG 178) of being offered clozapine after inadequate response to treatmen...
Clozapine Prescribing in the General Hospitals
Clozapine Prescribing in the General Hospitals
Aims:
Clozapine is an effective treatment for adults with schizophrenia, who have not responded to two other antipsychotic medications. However, there are chall...
Assessment of treatment outcomes and associated factors among patients treated with clozapine at amanuel mental specialized hospital, Addis Ababa, Ethiopia
Assessment of treatment outcomes and associated factors among patients treated with clozapine at amanuel mental specialized hospital, Addis Ababa, Ethiopia
Background
Clozapine is a medication used in psychiatry. It is the first atypical antipsychotic drug and the most effective in treatment resistant cases of schizophrenia and schizo...
Clozapine Prescribing in General Hospitals: A Second-Cycle Service Evaluation Following Quality Improvement Interventions
Clozapine Prescribing in General Hospitals: A Second-Cycle Service Evaluation Following Quality Improvement Interventions
Aims:
Clozapine is an effective medication for adults with treatment-resistant schizophrenia. However, its safe prescribing and monitoring can be challenging du...
Effectiveness of clozapine in neuroleptic-resistant schizophrenia: clinical response and plasma concentrations
Effectiveness of clozapine in neuroleptic-resistant schizophrenia: clinical response and plasma concentrations
Objective:
To assess the relation between plasma concentrations of clozapine and its 2 main metabolites, desmethyl clozapine and clozapine N-oxide, and clinical...
A Fatal Case of Bupropion Overdose
A Fatal Case of Bupropion Overdose
Abstract
Introduction: Bupropion is an aminoketone antidepressant that functions as a norepinephrine-dopamine reuptake inhibitor and FDA approved for the treatmen...

